Participating in research offers her hope of changing the course of lung cancer Jennifer Moran is married to her high school sweetheart. They have two teenage children in college. A photography major who once dreamed of working at National [...]
On August 11th, 2022, the Food and Drug Administration (FDA) approved Enhertu (fam- trastuzumab deruxtecan-nxki) for treatment of advanced non-small cell lung cancer (NSCLC) with an activating HER2 mutation for patients who have received one prior line of therapy. [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer Immunotherapy, a type of treatment that helps the body’s own immune system fight cancer, is often discussed as a first line of treatment for people with [...]
On March 4th, 2022, the Food and Drug Administration (FDA) approved Opdivo (nivolumab) for treatment before surgery in combination with platinum-based chemotherapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC). The approval was based on [...]
Author: Everett Moding, MD, PhD, Assistant Professor Department of Radiation Oncology, Stanford University School of Medicine A combination of chemotherapy and radiation therapy (chemoradiation therapy) is the backbone of treatment for non-small cell lung cancer (NSCLC) that has spread [...]
I was diagnosed with stage IV NSCLC adenocarcinoma on November 3, 2017 and found out I was ALK positive on November 26. Being diagnosed with lung cancer came as a total shock, especially since I am a non-smoker. My [...]
Author: Rashmi Acharya, MS, Science and Research Specialist, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly [...]